An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases
Authors:
- Lázaro Manuel FilgueiraLFLázaro Manuel Filgueira
- Julio Betancourt CervantesJCJulio Betancourt Cervantes
- Orlando Adolfo LovelleOLOrlando Adolfo Lovelle
- Carlos HerreraCHCarlos Herrera
- Jorge Alain CaballeroJCJorge Alain Caballero
- Naivy SánchezNSNaivy Sánchez
- Geidy LorenzoGLGeidy Lorenzo
- Meylan CepedaMCMeylan Cepeda
- Mayra RamosMRMayra Ramos
- Danay SaavedraDSDanay Saavedra
- 5 January 2021
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (4) , 289-295
Abstract
In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cel... Lay abstract In COVID-19 patients, inflammation is associated with the progression of the disease. This inflammation comes from immune system activation in response to SARS-COV-2. Itolizumab is an ...Keywords
Funding Information
- Center of Molecular Immunology
This publication has 27 references indexed in Scilit:
- Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and ItolizumabCurrent Drug Targets, 2016
- Immunological evaluation of rheumatoid arthritis patients treated with itolizumabmAbs, 2015
- Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled studyJournal of the American Academy of Dermatology, 2015
- Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III studyJournal of the American Academy of Dermatology, 2014
- Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabmAbs, 2014
- A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritisResults in Immunology, 2012
- CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interactionClinical and Experimental Immunology, 2010
- Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface ReceptorThe Journal of Immunology, 2006
- Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cellsBlood, 2006
- The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding SiteJournal of Biological Chemistry, 1995